REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
422.52
+3.90 (+0.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close418.62
Open418.21
Bid422.00 x 1100
Ask428.00 x 900
Day's Range416.00 - 423.64
52 Week Range281.89 - 431.32
Volume386,603
Avg. Volume717,732
Market Cap45.972B
Beta (3Y Monthly)0.97
PE Ratio (TTM)19.85
EPS (TTM)21.29
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est427.00
Trade prices are not sourced from all markets
  • bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacksyesterday

    bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.

  • Regeneron CEO Has Rewarded Shareholders Handsomely
    GuruFocus.com2 days ago

    Regeneron CEO Has Rewarded Shareholders Handsomely

    Regeneron Pharmaceuticals Inc. (REGN) shareholders ought to take time to toast the company's president and CEO, Leonard Schleifer. Schleifer earned $26.5 million in 2017, according to an article in Genetic Engineering & Biotechnology News. Warning! GuruFocus has detected 4 Warning Signs with REGN.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of REGN earnings conference call or presentation 6-Feb-19 1:30pm GMT

    Q4 2018 Regeneron Pharmaceuticals Inc Earnings Call

  • Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
    Zacks3 days ago

    Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

    Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.

  • What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
    Market Realist4 days ago

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.Copaxone

  • 3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
    Motley Fool6 days ago

    3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?

    These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?

  • PR Newswire8 days ago

    U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced two important legal developments invalidating Immunex patents with functional claims to antibodies that target human interleukin-4 receptors (IL-4R). Earlier today, the Opposition Division of the European Patent Office (EPO) revoked Immunex's European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision yesterday by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office (USPTO) to invalidate all 17 claims of Immunex's U.S. Patent No. 8,679,487 as obvious.

  • PR Newswire9 days ago

    Regeneron Announces Upcoming Investor Conference Presentation

    TARRYTOWN, N.Y. , Feb. 14, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its management presentation at the Cowen 39 th Annual Healthcare Conference at 11:20 a.m. ET ...

  • Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
    Zacks10 days ago

    Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

    Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

  • Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
    Zacks11 days ago

    Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

    Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

  • Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
    Zacks11 days ago

    Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?

    Is (REGN) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire11 days ago

    New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Regeneron will spend up to $490 million on manufacturing, labs this year
    American City Business Journals12 days ago

    Regeneron will spend up to $490 million on manufacturing, labs this year

    Regeneron spent $383.1 million on capital expenditures last year, an increase of $110 million from 2017.

  • Barrons.com12 days ago

    Regeneron’s 60% Price Cut Shows Heat Is Still on Drug Companies

    A growing effort to push back on price increases is affecting pharmaceutical companies. Regeneron and Sanofi are the latest to announce a cut, for the cholesterol drug Praluent.

  • Reuters12 days ago

    Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

    Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 (£4,533) a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.

  • PR Newswire12 days ago

    Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

    BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ -- Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.

  • Reuters12 days ago

    Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

    Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.

  • PR Newswire12 days ago

    Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price

    The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Regeneron and Sanofi committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.

  • Financial Times13 days ago

    [$$] Sanofi and Regeneron cut price of Praluent by 60%

    are slashing the list price of anti-cholesterol drug Praluent by 60 per cent, as the drugmakers respond to pressure from US health insurers and pharmacy benefit managers reluctant to adopt the costly medicine. Praluent will have a list price of $5,850 a year from early March, down from about $14,000 previously. The price cut is designed to make the drug more affordable for older patients using Medicare, cutting out-of-pocket costs to between $25 and $150 a month, depending on the plan.

  • PR Newswire14 days ago

    One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

    TARRYTOWN, N.Y. , Feb. 9, 2019 /PRNewswire/ --  Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious vision-threatening complications EYLEA diabetic ...

  • The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National
    Zacks15 days ago

    The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National

    The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $12.17 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • What Can We Expect From Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) Earnings In The Year Ahead?
    Simply Wall St.15 days ago

    What Can We Expect From Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) Earnings In The Year Ahead?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released itsRead More...

  • GuruFocus.com16 days ago

    Regeneron Pharmaceuticals Inc (REGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron Pharmaceuticals Inc had annual average EBITDA growth of 31.70% over the past five years.